Deciding Management for Early HER2-Positive Breast Cancer

Advantages of SC HER2 Therapy Over IV Administration in Breast Cancer

Rebecca A. Shatsky, MD, discusses the advantages of giving patients with HER2-positive breast cancer a subcutaneous injection of targeted therapy compared with the intravenous formulation of trastuzumab and pertuzumab.

Pharmacokinetics of Subcutaneous HER2 Therapy Noninferior in BC

Rebecca A. Shatsky, MD, discusses the outcomes of the phase 3 FeDeriCa study of subcutaneous trastuzumab and pertuzumab in patients with HER2-positive breast cancer.

Subcutaneous Regimen Shows Non-Inferiority for HER2+ Breast Cancer

Andrew Seidman, MD, discusses the FeDeriCa trial of intravenous versus subcutaneous trastuzumab and pertuzumab for neoadjuvant treatment of HER2-positive breast cancer.

Patients Prefer Subcutaneous Regimen for HER2-Positive Breast Cancer

Andrew Seidman, MD, discusses the PHranceSCa trial of patient preference for intravenous versus subcutaneous trastuzumab and pertuzumab for neoadjuvant treatment of HER2-positive breast cancer.

Subcutaneous Regimen Shows Noninferiority to Intravenous in HER2+ Breast Cancer

William J. Gradishar, MD, discusses the design and results of a study of intravenous versus subcutaneous pertuzumab and trastuzumab in patients with HER2-positive breast cancer.